Comparison of effect of metformin in combination with glimepiride and glibenclamide on glycaemic control in patient with type 2 Diabetes Mellitus

Abstract

The aim of the present study is to compare the effect of metformin in combination with Glimepiride and Glibenclamide In patient with type 2 Diabetes Mellitus. Subjects and method: This is an open-label, randomized study carried out to study the effect of metformin when it is given in combination with either glimepiride or glibenclamide on glycaemic control in patient with type 2 Diabetes Mellitus. Patients with Glycosylated Hemoglobin more than 7% were included in the study. 31 patients were randomly assigned for treatment based on metformin-glibenclamide 1000/10 mg tablets or metformin-glimepiride1000/2mg for 12 weeks. The comparisons were conducted between these two groups for HbA1C, FPG, PPG and lipid profile. Result: At week 12, the significant reductions in HbA1c were found in both groups but the patients treated with metformin-glimepiride resulted in significantly greater reductions in HbA1C (-1.4%) than metformin-glibenclamide (-1.2%). Also the greater significant reductions were observed in case of FPG, total cholesterole, serum triglyceride and LDL cholesterole in patient with metformin-glimepiride group. Conclusion: Metformin-glimepiride tablets resulted in significantly greater reductions in HbA1C and fasting plasma glucose compared with metformin plus glibenclamide in patients with type 2 diabetes mellitus.